mRNA-based therapeutics: powerful and versatile tools to combat diseases
S Qin, X Tang, Y Chen, K Chen, N Fan… - Signal transduction and …, 2022 - nature.com
The therapeutic use of messenger RNA (mRNA) has fueled great hope to combat a wide
range of incurable diseases. Recent rapid advances in biotechnology and molecular …
range of incurable diseases. Recent rapid advances in biotechnology and molecular …
The importance of RNA-based vaccines in the fight against COVID-19: an overview
BAS Machado, KVS Hodel, LMS Fonseca… - Vaccines, 2021 - mdpi.com
In recent years, vaccine development using ribonucleic acid (RNA) has become the most
promising and studied approach to produce safe and effective new vaccines, not only for …
promising and studied approach to produce safe and effective new vaccines, not only for …
[HTML][HTML] Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single …
G Zeng, Q Wu, H Pan, M Li, J Yang, L Wang… - The Lancet Infectious …, 2022 - thelancet.com
Background Large-scale vaccination against COVID-19 is being implemented in many
countries with CoronaVac, an inactivated vaccine. We aimed to assess the immune …
countries with CoronaVac, an inactivated vaccine. We aimed to assess the immune …
Waning of IgG, total and neutralizing antibodies 6 months post-vaccination with BNT162b2 in healthcare workers
Data about the long-term duration of antibodies after SARS-CoV-2 vaccination are still
scarce and are important to design vaccination strategies. In this study, 231 healthcare …
scarce and are important to design vaccination strategies. In this study, 231 healthcare …
Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines
Antibody responses are an important part of immunity after Coronavirus Disease 2019
(COVID-19) vaccination. However, antibody trajectories and the associated duration of …
(COVID-19) vaccination. However, antibody trajectories and the associated duration of …
Neutralizing antibodies in COVID-19 patients and vaccine recipients after two doses of BNT162b2
J Favresse, C Gillot, L Di Chiaro, C Eucher, M Elsen… - Viruses, 2021 - mdpi.com
The evaluation of the neutralizing capacity of anti-SARS-CoV-2 antibodies is important
because they represent real protective immunity. In this study we aimed to measure and …
because they represent real protective immunity. In this study we aimed to measure and …
[HTML][HTML] Dynamic SARS-CoV-2-specific B-cell and T-cell responses following immunization with an inactivated COVID-19 vaccine
Y Chen, S Yin, X Tong, Y Tao, J Ni, J Pan, M Li… - Clinical Microbiology …, 2022 - Elsevier
Objective The dynamic adaptive immune responses elicited by the inactivated virus vaccine
CoronaVac remain elusive. Methods In a prospective cohort of 100 healthcare professionals …
CoronaVac remain elusive. Methods In a prospective cohort of 100 healthcare professionals …
Pfizer-BioNTech and Sinopharm: a comparative study on post-vaccination antibody titers
COVID-19 (coronavirus disease 2019) vaccines induce immunity through different
mechanisms. The aim of this study is to compare the titers of specific antibodies in subjects …
mechanisms. The aim of this study is to compare the titers of specific antibodies in subjects …
Age and sex associations of SARS-CoV-2 antibody responses post BNT162b2 vaccination in healthcare workers: A mixed effects model across two vaccination …
C Anastassopoulou, D Antoni, Y Manoussopoulos… - PLoS …, 2022 - journals.plos.org
This study aimed to examine the associations with epidemiological, behavioral and clinical
parameters of IgG antibody responses against the spike protein of severe acute respiratory …
parameters of IgG antibody responses against the spike protein of severe acute respiratory …
Seroresponse to SARS-CoV-2 vaccines among maintenance dialysis patients over 6 months
Results Among 1870 patients receiving maintenance dialysis, 1569 had no prior COVID-19.
Patients without prior COVID-19 had declining titers over time. Among 443 recipients of …
Patients without prior COVID-19 had declining titers over time. Among 443 recipients of …